ArticleCureus2025
Grade 4 Mucositis Secondary to Methotrexate Use in a Pediatric Patient With Stage IV Burkitt Lymphoma: A Case Report.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Non-Hodgkin lymphoma (NHL) is a monoclonal neoplastic proliferation of lymphoid cells that can arise in different components of the immune system. Methotrexate (MTX), an antifolate agent, is widely used in the treatment of malignancies and autoimmune diseases. One of its most significant toxicities is gastrointestinal mucositis, a dose-dependent mucosal injury that can involve the entire alimentary tract and manifest as painful oral and intestinal ulcerations. We present the case of a pediatric patient with stage IV Burkitt lymphoma who developed severe mucocutaneous toxicity after MTX administration. This report also reviews risk factors associated with heightened toxicity and highlights strategies for prevention and management of MTX-induced oral mucositis, with particular emphasis on the clinical importance of delayed drug clearance, which increases the risk of multisystem toxicity and mortality.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.